摘要
目的分析p14蛋白在上尿路尿路上皮癌中的表达及其与患者临床病理特征和预后的关系。方法采用免疫组化检测341例上尿路尿路上皮癌(UTUC)患者中p14的表达。分析p14表达与临床病理特征、肿瘤无病生存(DFS)、肿瘤特异性生存(CSS)和膀胱内无复发生存(IVRFS)的关系。结果147例(43.1%)患者肿瘤细胞核中检测到p14的表达,p14与肿瘤多灶性(P=0.010)、肿瘤位于肾盂(P=0.013)、低病理T分期(P=0.001)、低肿瘤分级(P<0.001)、淋巴结转移(P<0.001)、乳头状肿瘤(P=0.001)、合并鳞状分化(P=0.017)有关。p14表达阳性是CSS的独立预测因素(HR=0.596,95%CI:0.381~0.934,P=0.024),DFS(HR=0.555,95%CI:0.395~0.778,P=0.001)和IVRFS(HR=0.527,95%CI:0.317~0.876,P=0.014)。结论UTUC中p14表达下调与肿瘤侵袭性生物学特征相关,p14表达阳性的UTUC患者往往具有更好的CSS、DFS和IVRFS。
Objective To evaluate p14 expression and its association with the clinicopathological characteristics and prognosis of upper tract urothelial carcinoma(UTUC).Methods The p14 expression was detected with immunohistochemistry(IHC)in a cohort of 341 UTUC patients.Associations of p14 expression with the clinicopathological characteristics,disease-free survival(DFS),cancer-specific survival(CSS)and intravesical recurrence-free survival(IVRFS)were analyzed.Results Among all 341 UTUC patients,p14 was detected in 147 cases(43.1%),which was correlated with multifocality(P=0.010),renal pelvis location(P=0.013),low pathological T stage(P=0.001),low tumor grade(P<0.001),lymph node metastasis(P<0.001),papillary tumor(P=0.001),and squamous differentiation(P=0.017).The p14 expression was an independent predictive factor for CSS(HR=0.596,95%CI:0.381-0.934;P=0.024),DFS(HR=0.555,95%CI:0.395-0.778,P=0.001),and IVRFS(HR=0.527,95%CI:0.317-0.876,P=0.014).Conclusion Downregulated p14 expression in UTUC is correlated with aggressive biological features of the tumor,and UTUC patients with p14 expression tend to have better CSS,DFS and IVRFS.
作者
鲍正清
方冬
杨新宇
何群
李学松
周利群
满立波
BAO Zhengqing;FANG Dong;YANG Xinyu;HE Qun;LI Xuesong;ZHOU Liqun;MAN Libo(Department of Urology,Beijing Jishuitan Hospital,Beijing 100035;Department of Urology,Peking University First Hospital,Institute of Urology,Peking University,National Urological Cancer Centre,Beijing 100034,China)
出处
《现代泌尿外科杂志》
CAS
2021年第11期966-971,共6页
Journal of Modern Urology
关键词
上尿路尿路上皮癌
P14
免疫组化
临床病理特征
预后
upper tract urothelial carcinoma
p14
immunohistochemistry
clinicopathological characteristic
prognosis
